The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Treatment Patterns and Trends for Spondylarthropathies

Treatment Patterns and Trends for Spondylarthropathies

April 6, 2012 • By Vanessa Caceres

  • Tweet
  • Email
Print-Friendly Version / Save PDF

CHICAGO—Methotrexate is a commonly used disease-modifying antirheumatic drug (DMARD) for treating patients with psoriatic arthritis (PsA). However, is it truly as effective as many think it is?

You Might Also Like
  • Where Will Kinase Inhibitors Fit into the RA Treatment Mix?
  • Rheumatology Drug Updates
  • Fellow’s Forum Case Report: Arthritis, Fever, and Weight Loss In a Teenager Suggest A Rheumatic Condition
Explore This Issue
April 2012
Also By This Author
  • Steven Echard Shares ACR Collaborative Plans at Florida Society Meeting

That’s the question that Gabrielle Kingsley, MB, PhD, consultant and reader in rheumatology at Kings College in London and Lewisham Healthcare NHS Trust, raised during the session, “Spondylarthropathies: Recent Insights,” which took place at the 2011 ACR/ARHP Annual Scientific Meeting in November. [Editor’s note: This session was recorded and is available via ACR SessionSelect at www.rheumatology.org.]

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

A number of PsA treatment guidelines include methotrexate, Dr. Kingsley said. The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis recommend methotrexate to treat peripheral disease and skin and nail disease in PsA, she noted. Guidelines from the Scottish Intercollegiate Guidelines Network state that dermatology and rheumatology teams should work together to use methotrexate in PsA for the treatment of severe cutaneous psoriasis and peripheral disease. Recommendations from the European League Against Rheumatism published last year also provide a role for methotrexate in PsA after nonsteroidal antiinflammatory drugs (NSAIDs) and glucocorticoid injections are used, Dr. Kingsley said.

“All of these guidelines have methotrexate, which implies a strong evidence base. The reality is somewhat different,” she said. Dr. Kingsley went on to explain that methotrexate seems to help symptoms in PsA patients but does not usually improve patient outcomes.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Kingsley reviewed the results of the Norwegian NOR-DMARD study that included 430 patients with PsA and 1,218 with rheumatoid arthritis (RA).1 Because it is known that methotrexate is effective in RA patients, it would make sense that it would have a similar effect on PsA patients, Dr. Kingsley said. The study found similar improvements in most measures for both patient groups, but when the data were adjusted for baseline, gender, and other factors, there was less improvement in the PsA patients, she said. However, changes were within the same range as they were for RA patients.

Dr. Kingsley then spoke of a randomized clinical trial in which she was involved that compared methotrexate with placebo in 221 PsA patients. Half of the patients had 15 mg of methotrexate a week, while the other half had the placebo. The investigators then looked at composite measures over six months.

The researchers found that, while methotrexate made improvements in symptom modification, it did not make statistically significant improvements with outcomes such as swollen joint count and tender joint count.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 | Single Page

Filed Under: Conditions, DMARDs & Immunosuppressives, Drug Updates, Spondyloarthritis Tagged With: ACR/ARHP Annual Meeting, Ankylosing Spondylitis, antiinflammatory, drug, Glucocorticoids, Methotrexate, patient care, Psoriatic Arthritis, Reactive arthritis, Rheumatoid arthritisIssue: April 2012

You Might Also Like:
  • Where Will Kinase Inhibitors Fit into the RA Treatment Mix?
  • Rheumatology Drug Updates
  • Fellow’s Forum Case Report: Arthritis, Fever, and Weight Loss In a Teenager Suggest A Rheumatic Condition
  • Drugs Studied for Use in Rheumatoid Arthritis, Weight Loss

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)